SG Americas Securities LLC Invests $555,000 in Denali Therapeutics Inc. $DNLI

SG Americas Securities LLC purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 38,201 shares of the company’s stock, valued at approximately $555,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Denali Therapeutics by 15.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after buying an additional 753 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Denali Therapeutics by 7.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company’s stock valued at $189,000 after acquiring an additional 930 shares in the last quarter. E Fund Management Co. Ltd. lifted its stake in Denali Therapeutics by 12.8% during the second quarter. E Fund Management Co. Ltd. now owns 13,612 shares of the company’s stock worth $190,000 after purchasing an additional 1,543 shares during the last quarter. California State Teachers Retirement System lifted its stake in Denali Therapeutics by 1.5% during the second quarter. California State Teachers Retirement System now owns 119,327 shares of the company’s stock worth $1,669,000 after purchasing an additional 1,792 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in Denali Therapeutics in the second quarter worth $26,000. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Stock Down 3.2%

Shares of DNLI stock opened at $20.25 on Friday. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of -6.96 and a beta of 1.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. The stock’s 50 day simple moving average is $17.88 and its 200 day simple moving average is $15.96. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $24.34.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.02. During the same period last year, the company posted ($0.63) EPS. Denali Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, research analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DNLI. BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Denali Therapeutics in a report on Friday, December 5th. UBS Group assumed coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday. Morgan Stanley restated an “overweight” rating and issued a $40.00 target price on shares of Denali Therapeutics in a research note on Thursday, January 8th. Finally, Stifel Nicolaus set a $37.00 price target on Denali Therapeutics in a research report on Monday, November 17th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $32.77.

Insider Buying and Selling at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares in the company, valued at $4,897,744.50. This trade represents a 10.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the transaction, the insider directly owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. This represents a 5.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 12.50% of the company’s stock.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.